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1. Introduction
Human leukocyte antigen (HLA) is the most polymorphic genetic system in humans, with
numerous alleles, and subsequently, various possible combinations [1]. These genes, the
products of histocompatibility complex (MHC) [2] are located in the short arm of chromo‐
some 6 at band p 21.3 [2] and are divided into three classes, I, II and III [1]. HLA class I is
responsible for coding the molecules HLA-A, -B and -C, present in almost all somatic cells
with killing of viral infected targets by class I antigens restrict cytotoxic T-cell (CD8+) func‐
tion [2] while HLA class II genes code the molecules HLA-DR, -DQ and -DP [1] by presenta‐
tion of exogenous antigens to T-helper cells (CD4+) or antigen presenting cells (APC) [2].
This polymorphism contributes to the differences in susceptibility to diseases among geneti‐
cally distinct groups [1]. The molecules coded for by the HLA system are responsible for the
antigen presentation [1]. The T lymphocytes that are linked to HLA molecules only recog‐
nize antigens by the antigen-specific cell surface receptor-antigens interaction [2], thus the
HLA antigens [1] and MCH molecules [2] apparently participate in controlling susceptibility
and resistance to various diseases. Some infectious diseases were considered as familial be‐
fore the finding of the causative microorganism and early twin studies indicated that there
was a substantial host genetic influence on susceptibility to diseases such as polio and tuber‐
culosis (TB) [3]. At present, it has been confirmed that human genetic variation demon‐
strates a major influence on the course of diseases caused by several infectious
microorganisms [3].
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2. Severe Acute Respiratory Syndrome and HLA
Recently, Itoyama et al reported that the deletion of the 287 bp Alu repeat (D allele) in intron
16 of the angiotensin converting enzyme 2 (ACE 2) gene is associated with hypoxemia and
diffuse alveolar damage in patients with severe acute respiratory syndrome (SARS) [4] and
may protect acute lung injury and respiratory failure [5]. Nevertheless, there may be poten‐
tial confounders to a genetic association study as the following: 1) the dead patients were
excluded from this study, 2) hypoxemia was defined as requiring oxygen supplementation,
and 3) only 44 patients were studied [6]. Some HLA subtypes, particularly HLA-B*0703 and
HLA-DRB1*0301 alleles have been demonstrated to be more prevalent in patients with SARS
[7] and those with poorer outcomes [8]. On the other hand, the polymorphism in ACE II
gene, coding for a functional receptor of the SARS-coronavirus, was not associated with the
susceptibility or outcome of SARS [9]. A previous study revealed that CXCL10(-938AA) gene
is always protective from SARS infection whenever it appears only jointly with either
Fg12(+158T/*) or HO-1 (-497A/*), whereas Fg12(+158T/*) is associated with higher SARS-in‐
fection susceptibility unless combined with CXCL10/IP-10(-938AA) which is associated with
lower susceptibility [10]. Chan et al concluded that the ACE I/D polymorphism was not di‐
rectly associated with increasing susceptibility to SARS-coronavirus infection and was not
associated with poor outcome after SARS-coronavirus infection [6]. A recent study in Tai‐
wan demonstrated that HLA-Cw*1502 [11], -DR*0301 [11], and -A*2402 [12] alleles conferred
resistance against SARS infection. CD209L homozygote individuals [13] and low-mannose-
binding-lectin-producing genotypes [14] have been demonstrated to have a significantly
lower risk and increased risk of SARS infection, respectively. A previous study among Viet‐
namese population with SARS revealed that polymorphisms of two interferon-inducible
genes, 2′, 5′-oligoadenylate synthetase 1 (OAS-1 (G-allele in exon 3 and the one in exon 6)) and
myxovirus resistance-A (MxA) were associated with SARS infection [15]. The single nucleotide
polymorphisms (SNPs) in MxA was associated with the progression of SARS [15]. The SNPs
in OAS-1 were associated with SARS-coronavirus infection or SARS development [15]. The
GG genotype and G-allele of G/T-SNP at position -88 in the MxA gene promoter were dem‐
onstrated more frequent in hypoxemic group of patients with SARS than non-hypoxemic
group [15]. They may be related to the response of SARS patients to interferons (IFNs), par‐
ticularly those with AA genotype of the A/G-SNP in exon 3 of OAS-1 may respond to IFN
treatment more effectively than those with AG or GG genotype [15]. If SARS re-emerges,
IFN could be a promising candidate to treat patients with SARS [16-23]. These findings may
contribute to the perception of IFN-induced antiviral response to SARS infection. SARS-co‐
ronavirus infection elicited both CD4+ and CD8+ T-cell responses to the M protein in recov‐
ered SARS patients that persisted for a long period of time [24]. This may have significant
implications in developing SARS vaccines [24]. A previous study indicated that a HLA-
A*0201-restricted decameric epitope P15 (S411-420, KLPDDFMGCV) derived from the S pro‐
tein that was found to localized within the angiotensin-converting enzyme 2 receptor-
binding region of the S1 domain could significantly enhance the expression of HLA-A*0201
molecules on the T2 cell surface [25]. P15 then stimulated IFN-γ-producing cytotoxic-T lym‐
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phocytes (CTLs) from the peripheral blood mononuclear cells of former SARS patients and
induced specific CTLs from P15-immunized HLA-A*2.1-transgenic mice in vivo [25]. Signifi‐
cant P15-specific CTLs then were induced by HLA-A*2.1-trangenic mice that was immu‐
nized by a deoxyribonucleic-acid (DNA) vaccine encoding the S protein [25]. This suggested
that P15 was a naturally processed epitope [25]. Thus, P15 could be a novel SARS-associated
coronavirus-specific epitope and a potential target for evaluation of candidate SARS vac‐
cines and characterization of virus control mechanisms [25].
3. Tuberculosis and HLA
HLA studies conducted in India revealed that there was association of HLA-DQ 1 and -DR 2
antigens with susceptibility of pulmonary TB [26]. A study in North Indian patients demon‐
strated that the allele DRB 1*1501 of HLA-DR 2 was higher compared with DRB 1*1502 [26]
whereas HLA-DQB 1*0601 ( a subtype of HLA-DQ 1), -DRB 1*1501 and DPB 1*02 were
demonstrated to be positively associated with pulmonary susceptibility among South Indian
patients [26]. Antigen processing gene 2 and mannose-binding protein (MBP) genes along with
HLA-DR2 have been associated with pulmonary TB [26]. Mannose-binding lectin-54 hetero‐
zygotes may be associated with protection against TB meningitis [26]. HLA-DQB 1*0601 and
HLA-DRB 1*0803 were associated with TB disease progression in Korean populations [27]. The
frequencies of HLA-DQB 1*0402 and antigens DR4 and DR8 were significantly decreased in
patients with pulmonary TB but the frequencies of HLA-DQA1*0101, -DQB1*0501, and -
DRB1*1501 were significantly increased in immunocompetent patients with pulmonary TB
[28]. An increased frequency of HLA-B*27 in the Greeks, HLA-A*2 and -B*5 in the Egyptians,
HLA-B*5, -B*15 and -DR*5 in the North American blacks, HLA-B*8 in the Canadians was
observed [26] whereas HLA-DQB1*0502 and -DQB1*0503 alleles were demonstrated among
the Thai and Vietnamese TB patients, respectively [26, 29]. HLA-B*17-tumor-necrosis-factor-
α-238/A, -tumor-necrosis-factor-α-308/2 and -tumor-necrosis-factor-β-2 have been shown to be
associated with TB bacteriological relapse among Indian population [30]. Recently, a novel
HLA-DR-restricted peptide E7 from the ESAT-6 protein of Mycobacterium tuberculosis before
and during TB treatment was used to prepare modified HLA-DR*08032/E7 and HLA-DR*0818/
E7 tetramers to monitor tetramer-positive CD4+ T-cells in direct staining of single specimen
and flow cytometric analyses and resulted in 0.1 to 8.8% in the initial pulmonary TB patients’
blood, 0.1 to 10.7% in pleural fluid of the initial tuberculous pleuritis patients, 0.02 to 2.2% in
non-TB patients’ blood, 0.02 to 0.48% in healthy donors’ blood and mostly resulted in 0 to 0.2%
in umbilical cord blood [31]. After 90-120 days of initial TB symptoms, levels of tetramer-
positive CD4+-T cells in tetramer-positive CD4+-T cells reached and kept at low even normal
at 0.03 to 0.3% [31]. Tetramer-positive, interferon-γ-producing and/or tumor-necrosis-factor-
α-producing CD4+-T cells in pulmonary granuloma, lymph node and cavernous tissues of TB
patients could be detected by in situ staining [31]. Sensitivity and specificity of tetramer
molecules should be confirmed in the future in order to develop possible diagnostic reagents
and research [31].
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4. Human Immunodeficiency Virus Infection (HIV)/Acquired
Immunodeficiency Syndrome (AIDS) — Related tropical pulmonary
infectious diseases and HLA
The World Health Organization (WHO) estimates that 8-10 million new cases of TB globally
occur each year [32]. Although AIDS is the same disease as HIV disease in all part of the world,
this microorganism is mostly in many tropical countries [32]. In tropical countries, TB and
bacterial pneumonia represent the major pulmonary infections among the patients with HIV-
infection/AIDS [32]. Although the spectrum of HIV disease/AIDS is quite broad, the majority
of the pulmonary infections in HIV-1 infected patients are similar to those observed in non-
HIV infected persons [32]. The geographical differences are primarily due to varying frequen‐
cies rather than the kinds of infections [32]. Of all the pulmonary infections encountered in the
tropics obviously Mycobacterium tuberculosis is one of the most significant pathogenic micro‐
organisms [32]. A recent study on HLA and AIDS in children with AIDS revealed that the
presence of homozygous HLA-B or -C alleles was associated with more rapid disease progres‐
sion, in contrast, the presence of HLA-B*27 or -B*57 alleles was associated with slower disease
progression which remained significant after adjustment for age, gender, race, and baseline
HIV-1 log ribonucleic acid (RNA), CD4+-T cell count and percent and weight for age Z score
or other genetic variants including CCR5-wt/Δ32 (CCR5 = chemokine (C-C motif) receptor 5),
-59029-G/A, CCR2-wt/64I (CCR2 = chemokine (C-C motif) receptor 2), CX3CR1-249-V/I (CX3CR1
= chemokine (C-C motif) ligand 3-like 1), -280-T/M, SDF-1-180-G/A (SDF-1 = stromal cell-
derived factor-1), MCP-1-G/A (MCP-1 = monocyte chemotactic protein-1), MBL2-A/O (MBL =
mannose-binding lectin), MBL2-X/Y (MBL = mannose-binding lectin), MBL2-P/Q (MBL =
mannose-binding lectin), and MBL2-H/L (MBL = mannose-binding lectin) [33]. Additionally,
the HLA-A*24 allele was associated with more rapid central nervous system (CNS) impairment
and the HLA-Cw2 allele protected against disease progression [33]. For HLA class II, the
presence of the HLA-DQB1*2 allele protected against both HIV-1 disease progression and CNS
impairment [33]. HLA concordance between a mother and her infant is associated with
increased risk of HIV transmission whereas HLA discordance decreases the risk of mother-to-
child HIV transmission [34, 35]. HLA class I homozygosity [36, 37] and children who have the
same HLA class I alleles at both sites with their mothers at one of more HLA locus [38] are at
increased risk for more rapid disease progression.
4.1. HIV-infection/AIDS-TB Co-infection and HLA
Studies from Haiti and sub-Saharan Africa have demonstrated that 17% to 66% of TB cases are
HIV-1 seropositive while 50% of HIV-seropositive patients with pulmonary symptoms are sick
with TB [32]. A previous study in Brazilians by Figueiredo et al revealed that HLA-A*31, HLA-
B*41, HLA-DQB1*5, and HLA-DRB1*10 alleles, were over- represented in acquired-immuno‐
deficiency-syndrome (AIDS) patients with TB, indicated that these HLA molecules are
associated with susceptibility to TB in Brazilian patients with AIDS [39].
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4.2. HIV-infection/AIDS-related community acquired pneumonia
A previous study in Kenya in 1976 demonstrated that 20% of patients presenting with
pneumonia to Kenyatta National Hospital had pneumococcal bacteremia which was very
common among HIV-infected patients (26% of the HIV-1 seropositive group versus 6% of the
seronegative group) [40] whereas Streptococcus pneumoniae pneumonia has been the most
common cause of bacterial pneumonia same as in the pre-AIDS era [32]. Approximately, 17%
of medically hospital admissions to the one of East Africa’s largest hospital are community
acquired pneumonia (CAP) [32]. Gilks et al reported that invasive pneumococcal disease
among the female prostitutes in Nairobi, Kenya was the most frequently encountered serious
HIV-associated infection and was more common than TB [40]. Pneumococcal pneumonia
occurred at a significantly higher rate among HIV- seropositive patients, particularly HIV-1
serotype [40]. The clinical presentation of pyogenic pneumonia in HIV-1 seropositive patients
was similar to that observed in HIV-seronegative ones [40]. The acute onset of fever and cough
was the most common presentation [40]. Although, approximately, 10% of patients with lobar
pneumonia in the tropics fail to improve with penicillin treatment, there is no significant
difference in penicillin treatment response in both HIV-seropositive and HIV-seronegative
patients [40]. In tropical and developing countries, penicillin, because of it antimicrobial
tolerance and cheapness, is still the drug of choice for CAP regardless of HIV status [40]. The
mortality rate was higher among HIV-1 seropositive patients with CAP than HIV-1 seroneg‐
ative persons with CAP (17% versus 8%) [40]. Recurrence of pneumococcal disease occurred
22% among the prostitutes in Nairobi, Kenya which rate of recurrence increased both in Kenya
and the United States of America [40].
4.3. HIV-infection/AIDS-related pulmonary Nocardia asteroides infectionasteroides
infection
Nocardiaasteroides is a branching filamentous, beaded Gram-positive-rod microorganism
which is usually found worldwide in soil and decaying organic matter and usually produces
disease in immunocompromised persons, particularly HIV-1 infected individuals although
few cases have been reported from the tropical regions [32]. The earliest report of AIDS patients
from Rwanda demonstrated one of 26 cases diagnosing Nocardia asteroides pleuropneumonia
whereas one of 50 AIDS patients with pulmonary interstitial infiltrates in Zimbabwe was
diagnosed pneumonia [32]. In previous studies in Uganda, Cote d’ Ivoire, and Zaire, three of
the 57, one of 52, and occasional AIDS patients who underwent post-mortem examination
revealed histopathologically pulmonary military nocardiosis, respectively [32]. Clinical
manifestations of pulmonary nocardiosis in HIV-1 infected patients are usually non-specific
[32]. The majority of cases present with fever, cough, night sweats, malaise, and body weight
loss [32]. Although nocardiosis is frequently disseminated at the presentation, the lungs are
the most common site of involvement, particularly upper lobes [32]. Thus, pulmonary
nocardiosis is roentgenographically indistinguishable from pulmonary TB [32]. Because of
rarely positive-blood culture, culture of the respiratory specimens is the definitely diagnostic
method [32]. Due to 47% of patients was indicated of nocardiosis so the diagnosis should be
suspected if the characteristic morphology is detected on Gram staining [41]. This microor‐
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ganism is also weakly stains the acid fast [32]. According to ability to stain the acid fast coupled
with the roentgenographic presentation of this microbial pulmonary infection, it may contrib‐
ute to be misdiagnosed as pulmonary TB [32]. It is likely that sulphonamides (trimethoprim-
sulphamethoxazole) will be effective in HIV-1 infected patients with nocardiosis whereas
sulphonamides have been the treatment of choice for nocardiosis in non-HIV-1 infected
patients [32]. Other antimicrobial agents with in vitro bactericidal activity to Nocardia ÿste‐
roids include amoxicillin-clavulanic acid, minocycline, amikacin, and third-generation
cephalosporin [32]. Treatment duration is at least 6 to 12 months and, perhaps, indefinitely
since recurrences have been reported [32].
4.4. HIV-infection/AIDS-related pulmonary melioidosis
Melioidosis is caused by the Gram-negative motile bacillus, Burkholderia (Pseudomonas)
pseudomallei [32]. A previous study in Bangkok, Thailand, 49 cases were observed between
1975 and 1987 [32]. Of these patients, 20 had localized disease while 29 had disseminated
disease [32]. Almost all of these patients had an underlying immunocompromised condition
like hematological malignancy, collagen vascular disease, and diabetes mellitus [32]. One case
had AIDS and presented with left lung infiltrates and recurrent bacteremic melioidosis [32].
More than 750 cases of melioidosis have occurred during the last two decades, and over 75%
of the patients were farmers [32]. The disease is endemic in southeast Asia, west Africa, and
northern Australia [32]. The clinical manifestations of melioidosis are non- specific but in
immunocompromised patients, they usually present with fever and pulmonary infiltrates [32].
The roentgenographic presentation is also non-specific and may demonstrate diffuse infil‐
trates, hilar adenopathy, lung abscess, or extensive pneumonia, thus the diagnosis requires
isolation of this microorganism, particularly by culture of blood and/or respiratory samples in
cases with disseminated disease [32]. A previous study by Cheepsattayakorn et al at the 10th
Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand in 2001 among a number
of patients with clinical and roentgenographic presentations mimicked Burkholderia (Pseudo‐
monas) pseudomallei pneumonia revealed no detection of the laboratory-confirmed cases but
having dramatic response to 6-12 months of tetracycline treatment [42]. A previous study in
Thailand reported that 14 immunocompromised melioidosis patients with disease dissemi‐
nation had a treatment delay or were appropriately treated, all but one were dead [32]. Thus,
rapid and early diagnosis and treatment with combined antimicrobials is crucial [32]. It should
be emphasized that most HIV- infected/AIDS patients in Thailand are urban dwellers and that
most melioidosis cases occur in farmers [32]. Thus, the incidence of melioidosis is expected to
increase as the HIV epidemic spread into rural area [32]. Burkholderia (Pseudomonas) pseudo‐
mallei is usually susceptible to tetracycline, chloramphenicol, trimethoprim-sulphamethoxa‐
zole, and third-generation cephalosporin [32]. If the patient is seriously clinical toxic, two
antimicrobials are usually recommended during the initial 30 days and followed by 60-150
days of trimethoprim-sulphamethoxazole alone [32]. In septicemic melioidosis, trimethoprim-
sulphamethoxazole plus a third-generation cephalosporin are recommended [32]. For patients
who are intolerant to trimethoprim-sulphamethoxazole, another antimicrobial listed above
should be replaced [32].
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4.5. HIV-infection/AIDS-related fungal pneumonia
4.5.1. Pulmonary histoplasmosis
Histoplasma capsulatum is a dimorphic soil dwelling fungus which is rare in Africa before the
AIDS epidemic [43]. This microorganism is endemic in the Americas [43]. Histoplasmosis
was reported in 1984 in a Zairean AIDS patients and subsequently was identified in a few
post-mortem-examined lungs in Zaire [43]. African histoplasmosis is also caused by Histo‐
plasma duboisii, a fungal disease which is not increased in Congo but occurs mainly in Cen‐
tral and West Africa [44]. Carme et al reported a 26-year-old Congolese male with
disseminated Histoplasma duboisii infection [45]. In 1987, a white heterosexual European pa‐
tient was reported with African histoplasmosis [46, 47]. Three Belgian AIDS patients who
had lived in Africa disseminated Histoplasma duboisii infection whereas one of these patients
developed pulmonary disease [48]. An African HIV-2 infected child from Guinea Bissau was
reported with disseminated disease [46]. Amphotericin B remains the drug of choice for the
treatment of histoplasmosis with AIDS [49]. Ketoconazole, with or without a prior course of
amphotericin B, has been used, but sometimes with unacceptable results [50]. After induc‐
tion therapy, patients should be maintained on lifelong maintenance therapy with either
weekly intravenous amphotericin B, oral itraconazole, or oral fluconazole [50].
4.5.2. Pulmonary cryptococcosis
Cryptococcus neoformans, a budding encapsulated yeast is distributed worldwide [50]. In Hai‐
ti, the prevalence of cryptococcosis among AIDS patients was approximately 13% whereas
as many as 30% of AIDS patients in some areas of subsahara Africa had cryptococcosis [51].
Most of the patients present with disseminated disease or meningitis although the lungs is
the usual portal of entry, thus, isolated pulmonary involvement is unusual [32]. A previous
study in Bujumbura, Burundi demonstrated that only one patients of 222 cases was diag‐
nosed cryptococcal pneumonia [52] while two of 40 Ugandan patients in a previous study
were diagnosed cryptococcal pneumonia [53] but no cases with pulmonary cryptococcosis
in Cote d’ Ivoire was reported in a post-mortem study [54]. Previous data from Rwanda in‐
dicated that cryptococcal pneumonia was common in this country [55, 56]. Between January
1990 and March 1992, 28 Rwandese HIV-1 infected patients were diagnosed cryptococcal
pneumonia by isolation from sputum, pleural fluid, and bronchoalveolar lavage (BAL) [55].
The serum cryptococcal antigen testing was negative in all patients without extrapulmonary
site of infection [55]. Generally, there are two varieties of Cryptococcus neoformans, and gattii
[57]. Most HIV-1 infected cases were reported of neoformans variety [57]. Variety gattii is
mainly restricted to tropical and subtropical areas [57]. Since 1987, six cases of variety gattii
have been reported from Rwanda, Brazil, and Zaire [57]. One Rwandese patient with nega‐
tive serum and cerebrospinal fluid cryptococcal antigen demonstrated right hilar adenop‐
athy accompanying a right lower lung infiltrate [57]. Cryptococcus neoformans variety gattii
was isolated from the BAL fluid when the patient did not respond to penicillin and trime‐
thoprim-sulphamethoxazole [57]. Taelman et al demonstrated that itraconazole( 200 mg/
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day) was effective in preventing future disease dissemination for Rwandese patients with
isolated pulmonary cryptococcosis [56]. Fluconazole (400-800 mg/day) has been shown to be
effective as primary treatment as well as long-term therapy (200- 400 mg/day) [50]. In the
USA, the drug of choice for treatment of cryptococcosis is amphotericin B, with or without
flucytosine [50]. Nevertheless, these antimicrobials are frequently not available in tropical
countries [50].
4.5.3. Pulmonary paracoccidioidomycosis
Paracoccidioidomycosis is caused by the dimorphic fungus Paracoccidioides brasiliensis [58].
The patients with paracoccidioidomycosis may present with cutaneous form, isolated pul‐
monary involvement, or disseminated form [58]. Most patients present with disseminated
involvement [58]. Only few cases involving HIV-1 infection have been reported despite its
endemicity [58]. The chest roentgenographic findings demonstrate notable diffuse reticulo‐
nodular infiltrates, and sometimes with hilar adenopathy [59]. Patients have been success‐
fully treated with various regimens including amphotericin B, imidazole compounds, and
sulphadiazine [60]. Itraconazole (100 mg/day) appears to be more effective than ketocona‐
zole (200-400 mg/day) which has been successfully used to treat paracoccidioidomycosis in
immunocompetent patients with unknown treatment duration [60]. Nevertheless, the rec‐
ommended treatment duration is 6 to 18 months [60]. At least two patients have been placed
on suppressive therapy with sulphadiazine (1-6 g/day) for lifelong prophylaxis with good
early results [60].
4.5.4. Pulmonary penicillosis
This disease caused by the usual dimorphic fungus, Penicillium marneffei, both in normal and
immunocompromised hosts [61]. This fungus is endemic to southeast Asia and southern
China [61]. Most cases have been reported as a systemic mycoses [61]. A previous study
from Thailand demonstrated that 11 of the 21 patients had a cough as their presentation [61].
Of the 6 cases with abnormal chest roentgenographic findings, 3 showed diffuse reticulo‐
nodular infiltrates, 2 had localized interstitial infiltrates, and 1 had a focal alveolar infiltrate
[61]. Definite diagnosis is usually made from cultures of blood, bone marrow, or skin biopsy
[61]. The current treatment of choice is 6-8 weeks of Amphotericin B (40 mg/kg) [32]. In in
above study in Thailand by Supparapinyo et al, 6 of 8 patients who were treated with Am‐
photericn B responded well [61]. Nevertheless, 6 of 9 patients who were treated with 400 mg
itraconazole for eight weeks also well responded [61]. Unfortunately, 4 patients died before
treatment started [61]. Penicillium marneffei infection may become more common as HIV-in‐
fection/AIDS move into rural areas as with melioidosis [32].
4.5.5. Pneumocystis jeroveci (carinii) pneumonia (Pulmonary pneumocystosis)
Currently, the taxonomy of Pneumocystis jeroveci (carinii) is in question, but recent data dem‐
onstrated it is closely related to fungus [62]. Generally, Pneumocystis jeroveci (carinii) is a
ubiquitous microorganism found every region of the world [63]. During the course of HIV
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disease/AIDS, 75% of the patients may develop Pneumocystis jeroveci (carinii) pneumonia
(PCP) [64]. A previous study by Cheepsattayakorn et al at the 10th Zonal Tuberculosis and
Chest Disease center, Chiang Mai, Thailand between 1999 and 2000 among 49 HIV-infected/
AIDS patients who had clinical manifestations and chest roentgenographic findings compat‐
ible with PCP revealed that only one patient demonstrated induced sputum-reverse tran‐
scriptase polymerase chain reaction (RT-PCR)- confirmed PCP whereas two patients were
confirmed by blood RT-PCR [65]. Nevertheless, the frequency of PCP is quite different in
tropical countries [66]. Blaser et al reported that 20% of PCP occurred among HIV-infected/
AIDS individuals native to the tropics (35%) was significantly lower than for HIV-infected/
AIDS individuals in more developed countries (73%) [66]. PCP has been detected in 37% of
AIDS patients of African origin in the USA and in 14-24% of African patients with AIDS
treated in Europe [67]. The question is whether the exposure to Pneumocystis jeroveci (carinii)
occurred in Africa or after leaving is not known. A previous study from Zimbabwe reported
that of 50 HIV-infected/AIDS patients with acute interstitial pneumonia, 17 and 16 were di‐
agnosed PCP and TB, respectively [68]. By using sputum induction with hypertonic saline,
researchers in Tanzania reported that 3 of 83 specimens (3-6%) were positive for Pneumocys‐
tis jeroveci (carinii) [69]. A number of previous studies in 229 AIDS cases from Haiti indicated
that PCP was detected in only 7% of 131 cases compared with 71% of the first 80 AIDS pa‐
tients noted at the New York Hospital in New York City, USA [70]. Chequer et al reported
their study in Brazil of 2,135 adult AIDS patients and demonstrated that 425 cases (20%)
were diagnosed PCP whereas PCP plus another infection was detected in 265 cases (12%)
[71] whereas 45% of homosexual urban AIDS patients in southern Brazil were diagnosed
PCP [72]. The clinical and roentgenographic presentations of PCP are likely to be similar
among the different regions [68]. Nevertheless, the frequent occurrence of TB in developing
countries makes differentiation of the two diseases difficult [68], but in one study, the clini‐
cal picture most consistent with PCP was a respiratory rate of over 40/minute [68]. In con‐
trast, the coarse reticulonodular infiltrates on the chest roentgenogram is most likely to be
TB [68]. Currently, the treatment of choice for PCP is trimethoprim-sulphamethoxazole [32].
Other alternative antipneumocystis drugs are often not available in the tropical countries
[32]. It has been postulated that HIV-infected/AIDS patients in the tropics die before they be‐
come immunocompromised enough to develop PCP [54, 73, 74].
4.6. HIV-infection/AIDS-related parasitic pneumonia
4.6.1. Pulmonary strongyloidiasis
Very few parasitic diseases have been reported to cause pneumonia in HIV- infected/AIDS
patients [32]. A helminth, Strongyloides stercoralis which is commonly found in many tropical
and subtropical areas, has occasionally been reported as the cause of pulmonary disease
[32]. The prevalence of this helminth in stool specimen varies from region to region as the
following : 26-48% in subsahara Africa, 15-82% in Brazil, 1-16% in Ecuador, and 4-40% in the
USA [75]. Although the prevalence of strongyloides infection in southeast Asia is high, but
no cases have been reported in the English language literature [32]. There have been rela‐
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tively few cases reported of helminth infection in AIDS patients in the tropics despite its
high prevalence [32]. In a previous study in Brazil, 10% of 100 AIDS patients were infected
with Strongyloides stercoralis [76] whereas in a study in Zambia, 6% of 63 HIV-infected pa‐
tients with chronic diarrhea were infected with Strongyloides stercoralis [77]. The parasitic fe‐
males live in the mucous membrane (wall) of small intestine of humans, particularly in the
lamina propria of the duodenum and proximal jejunum whereas the parasitic males remain
in the lumen of the bowel and they have no capability to penetrate the mucous membrane
[78]. The rhabditiform larvae that emanating from the eggs pierce the mucous membrane
and reach the lumen of the bowel [78]. These larvae are then passed with feces and can pen‐
etrate the intestinal epithelium or perianal skin without leaving the host by metamorphos‐
ing into filariform larvae in the lumen of small intestine [78]. This contributes to
autoinfection and persistence of infection for 20 to 30 years in individuals who have left the
endemic regions [79]. Most patients with hyperinfection present with cough, fever, and
breath shortness and usually diffuse pulmonary infiltrates [80]. The definite diagnosis is
identifying the helminth in the respiratory specimens or stool [80]. Previous reports demon‐
strated that at least two cases with strongyloides hyperinfection had concomitant PCP [81,
82]. In a previous review of the literature revealed that only surviving patients were treated
with thiabendazole, 25 mg/kg twice a day for five days with three courses 10 days apart fol‐
lowed by monthly course of thiabendazole whereas the duration of treatment in HIV-1 in‐
fected individual is unknown [82]. Generally, most patients have died directly or indirectly
from their strongyloides hyperinfection [82]. It seem cautious to treat any patient who is in‐
fected with Strongyloides stercoralis detected in the stool despite the rarity of clinically signifi‐
cant strongyloides infection in HIV-infected/AIDS patients [82].
4.6.2. Pulmonary ascariasis
Ascaris lumbricoides is the most common intestinal helminthic infection [83]. Both fertilized
and unfertilized eggs are passed in the feces and released in the soil [84]. Infection occurs
through soil contamination of hand or food with eggs and then swallowed [84]. The eggs
hatch into larvae in the small bowel, call “ first stage “, then moult into second-stage larvae
in the lumen of the small bowel. The second-stage larvae penetrate the wall of the intestine
and migrate via lymphatics and capillaries to the hepatic circulation and to the right side of
the heart and then reach the lungs [84]. The second-stage larvae larvae moult twice more in
the alveoli to produce third- and fourth-stage larvae. The fourth-stage larvae which are
formed 14 days after ingestion migrate upward to the trachea and then are swallowed to
reach back the small bowel [84]. The fourth-stage larvae take approximately 10 days for mi‐
gration from the lungs to the small intestine [84]. It takes 10-25 days to produce eggs after
initial ingestion [84]. The migrating larvae can induce tissue- and lung- granuloma forma‐
tion with macrophages, neutrophils, and eosinophils [85]. This may produce a hypersensi‐
tivity in the lungs and result in peribronchial inflammation, increased bronchial mucus
production and finally, bronchospasm [85]. Ascaris lumbricoides can produces both specific
and polyclonal IgE [85]. Elevation of IgG4 levels in patients with ascariasis have also been
reported [86]. Symptomatic pulmonary involvement may range from mild cough to a Lof‐
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fler’s syndrome which is a self-limiting lung inflammation and is associated with blood and
pulmonary eosinophilia, particularly childhood ascariasis [87, 88]. This syndrome can occur
as a result of exposure to various drugs. Clinical Presentation may vary from malaise, fever,
loss of appetite, myalgia, and headache [87, 88] to respiratory symptoms which include spu‐
tum-productive cough, chest pain, hemoptysis, shortness of breath, and wheezing [89].
Chest roentgenographic findings usually demonstrate peripherally basal opacities, but occa‐
sionally show unilateral, bilateral, transient, migratory, non-segmental opacities of various
sizes [90].
4.6.3. Pulmonary ancylostomiasis
4.6.3.1. Ancylostoma duodenale
Ancylostoma duodenale can live only one year [91, 92]. Female Ancylostoma duodenale produces
10,000 to 30,000 eggs per day [91, 92]. Man is the only definite host [91, 92]. Ancylostoma duo‐
denale larvae can enter the human host via the oral route in addition to the entry through the
skin and reach pulmonary circulation through the lymphatics and venules [91]. Ancylostoma
duodenale larvae can developmentally get arrested in the intestine or muscle and restart de‐
velopment when environmental conditions become favorable [93]. Bronchitis and bronchop‐
neumonia can occur when the larvae break through the pulmonary capillaries to enter the
alveolar spaces [32, 91, 92]. Pulmonary larval migration can develop peripheral blood eosi‐
nophilia [32, 91, 92]. Hookworm larvae can release a family of protein called “ ancylostoma-
secreted proteins (ASP) ” [32, 91, 92] and can secrete low-molecular weight polypeptides
which inhibit clotting factor Xa and tissue factor VIIa [94]. During pulmonary larval migra‐
tion, the patients may present with cough, fever, wheezing, and transient pulmonary infil‐
trates that is associated with blood and pulmonary eosinophilia [32]. Both albendazole
(single dose of 400 mg) and mebendazole (100 mg twice daily for three days) are drug of
choice for treatment of hookworm [32]. Pyrantel pamoate (single dose of 11 mg/kg with
maximum dose of 1 g, orally) is an alternative drug of choice [32]. A previous study re‐
vealed that ivermectin can effectively treat hookworm infections [32].
4.6.3.2. Necator americanus
Necator americanus larvae can infect human only through the skin [91]. The larvae reach the
lungs same mechanisms as the Ancylostoma duodenale [32]. The interval between the time of
skin penetration and laying of eggs by adult worms is about six weeks [32]. Bronchitis and
bronchopneumonia can occur when the larvae break through the pulmonary capillaries to
enter the alveoli [32]. Drugs of choice for treatment of Necator americanus are the same as the
drugs of choice for treatment of Ancylostoma duodenale [32].
4.6.4. Pulmonary paragonimiasis
In Asia, nearly 20 million people are infected with Paragonimus species such as Paragonimus
westernmani which is the main species in humans, Paragonimus mexicanus, Paragonimus africa‐
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nus, Paragonimus miyazakii, Paragonimus phillipinensis, Paragonimus kellicotti, Paragonimus
skrjabini, Paragonimus heterotremus, and Paragonimus uterobilateralis [95-97]. Paragonimiasis is
a food-borne zoonoses [32]. Humans get Paragonimus species when ingest raw crayfishes or
crabs infected with infective metacercariae [95]. The parasite from the human gut passes
through several organs and tissues to reach the lungs [95]. Adult worm live in the lungs and
the eggs are voided in the sputum or feces [95]. Pulmonary paragonimiasis manifests as
chronic cough, hemoptysis, chest pain, and fever [98]. Pneumothorax or pleural effusion is
an important manifestation in paragonimiasis [99]. Chest roentgenographs may demon‐
strate infiltrates, nodules, and cavities [100]. The parasitic eggs can be shown in sputum
specimens, bronchoalveolar lavage fluid or lung biopsy specimens [32].Peripheral blood eo‐
sinophilia and elevated serum IgE levels are demonstrated in more than 80% of cases with
paragonimiasis [95, 99]. Paragonimus westernmani adult excretory-secretory products are
composed of cysteine proteases which are involved in immunological reactions during para‐
sitic infection [101, 102]. Immunoglobulin G4 antibodies to an excretory-secretory product of
Paragonimus heterotremus had accuracy, sensitivity, specificity, and positive and negative
predictive values of 97.6%, 100%, 96.9%, 90%, and 100%, respectively [103]. Paragonimiasis
can be treated with praziquantel 75 mg/kg/day for three days), triclabendazole (20 mg/kg in
two equal doses), niclofolan (2 mg/kg as a single dose), or bithionol (30 to 40 mg/kg in 10
days on alternative days) [95, 104, 105].
4.6.5. Pulmonary schistosomiasis
Schistosoma species that cause human disease are Schistosoma hematobium, Schistosoma japoni‐
cum, and Schistosoma mansoni [106]. The schistosome eggs are passed in feces (Schistosoma ja‐
ponicum and Schistosoma mansoni) or in urine (Schistosoma hematobium) [32]. The infective
cercariae in water are ingested to penetrate the human gut or penetrate human skin and fi‐
nally reside at the mesenteric beds (Schistosoma japonicum and Schistosoma mansoni) and the
urinary bladder vesicle beds (Schistosoma hematobium) [32]. Pulmonary schistosomiasis can
clinically present as acute or chronic form [32]. Acute manifestations, called “ Katayama
syndrome ” can develop three to eight weeks after skin penetration [107, 108]. The acute
form presents with dry cough, wheezing, shortness of breath, chill, fever, weight loss, ab‐
dominal pain, diarrhea, urticarial, myalgia [108, 109], and small pulmonary nodules in chest
roentgenographs or computed tomography in immunocompromised patients [110]. Patients
with chronic form present with pulmonary hypertension and cor-pulmonale [111, 112]
whereas massive hemoptysis and lobar consolidation and collapse have been reported [113].
Hepatosplenomegaly due to portal hypertension has been reported in patients infected with
Schistosoma japonicum and Schistosoma mansoni [106]. In chronic form, peripheral blood eosi‐
nophilia with mild leukocytosis, IgE levels, and abnormal liver function test are reported
[106]. Acute and chronic schistosomiasis can be treated with corticosteroids alone followed
by praziquantel (20-30 mg/kg orally in two doses within 12 hours) and then praziquantel is
repeated several weeks later to eradicate the adult flukes [106]. Acute form can be treated
with artemether, an artemisinin derivative [106].
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4.6.6. Pulmonary hydatid disease
Human hydatid disease is caused by Echinococcus multilocularis and Echinococcus granulosus
[32]. Hydatid cysts are mainly formed in the lungs and liver [32]. Pulmonary alveolar echino‐
coccosis (AE) is caused by hematogenous spreading from hepatic lesions [114]. The adult
Echinococcus granulosus resides mainly in the small gut of the dogs [32]. Humans are infected
by ingestion of parasitic eggs excreted in the feces of the dogs [32]. Clinical pulmonary
manifestations include cough, dyspnea, chest pain, and fever [32]. Rupture of hydatid cysts
into a bronchus may result in expectoration of cystic fluid containing parasite membrane,
hemoptysis, asthma-liked symptoms, respiratory distress, persistent pneumonia, anaphylactic
shock, and sepsis [115, 116] and elevation of IgG and eosinophilia [117]. Immunodiagnostic
tests using purified Echinococcus granulosus antigens have preferable sensitivity and specificity
for the diagnosis of AE [118]. Chest roentgenographs demonstrate solitary or multiple round
opacificaties mimicking lung tumors [119]. It has been experimentally revealed that magnetic
resonance imaging can detect early pulmonary AE [120]. Many year-treatment with meben‐
dazole, praziquantel or albendazole is useful, particularly in inoperably recurrent and multiple
cysts, but treatment of hydatid cyst is primary surgical [121]. The treatment of AE is radical
surgical resection of entire parasitic lesion [121] but should avoid segmentectomy, lobectomy,
and pneumonectomy [122-124].
4.6.7. Pulmonary trichinellosis
The most important species that infect humans is Trichinella spiralis [125]. Humans get parasitic
infection from ingestion of raw and infected pig’s muscle containing larval trichinellae [126].
The larvae develop into adults in the duodenum and jejunum [126]. The larvae undergo
encystment in the muscle and a host capsule develops around the larvae and later on may get
calcified [126]. Clinical pulmonary features include cough, dyspnea, and pulmonary infiltrates
on the chest roentgenographs [127]. The important laboratory findings are elevation of serum
aminotransferase, serum adolase, serum lactate dehydrogenase, and serum creatine phospho‐
kinase, leukocytosis, and eosinophilia [127]. An enzyme-linked immunosorbent assay (ELISA)
for identification of anti-Trichinella antibodies using excretory-secretory antigens may be
useful in the diagnosis of Trichinella spiralis infection [128], a definite diagnosis can be per‐
formed by muscle biopsy (preferably deltoid muscle) [127]. Treatment of choice is with
mebendazole, 200 to 400 mg, three times a day for three days followed by 400 to 500 mg, three
times a day for 10 days [32]. The alternative drug of choice is albendazole, 400 mg per day for
three days followed by 800 mg per day for 15 days [32]. Symptomatic treatment of trichinosis
is analgesics and corticosteroids [32].
5. Filarial parasites — Related tropical pulmonary eosinophilia and HLA
This syndrome results from immunological hyperresponsiveness to human filarial parasites,
Wuchereria bancrofti and Brugia malayi [129]. Tropical pulmonary eosinophilia (TPE) is one of
the main causes of pulmonary eosinophilia in the tropical countries and is prevalent in filarial
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endemic regions of the world particularly Southeast Asia [129, 130]. Clinical findings are
cough, fever, chest pain, and body weight loss in association with massive blood eosinophilia
[131]. Chest roentgenographs demonstrate military infiltrates of both lungs mimic military TB
[132]. Additionally, there may be prominent hila with heavy vascular markings [133-136], but
20% of cases present with normal chest roentgenographs [137]. Some previous studies of
computed tomographic scan of the chest demonstrated air trapping, mediastinal lymphaden‐
opathy, calcification, and bronchiectasis [138]. At least 120 million people are globally infected
with mosquito-borne lymphatic filariasis [137], but only less than 1% of filarial infection causes
TPE [139] whereas various studies have demonstrated that filarial infection is the cause of TPE
[129, 140]. A positive immediate reaction to intradermal skin tests with Dirofilaria immitis
antigens have been demonstrated in patients with TPE [141]. Microfilariae, anatomical features
of Wuchereria bancrofti had demonstrated in the lungs, liver, and lymph nodes of the patients
with TPE [142-144], but are rarely identified in the blood [142]. A recent study revealed that
the CD45RA+ and CD45RA- effector cells in patients with chronic lymphatic filarial infection
demonstrated a reduced activation state based on their lower expression of HLA-DR, con‐
trasting with findings identified in patients with HIV-1 infection [145]. An inverse correlation
between the percentage of CD8+ HLA-DR+ lymphocytes pokeweed mitogen-induced prolif‐
eration was observed [146]. These findings indicated that activated CD8+- T lymphocytes may
be involved in the pathogenesis of chronically obstructive lymphatic form of filariasis [146]. A
previous study conducted by Sasisekhar et al demonstrated that monocytes from microfilare‐
mic (MF) patients revealed an inability to respond to lipopolysaccharide compared to mono‐
cytes from endemic normal individuals of from patients with lymphedema [147]. Serum from
MF patients demonstrated reduction of adherence and spreading of normal monocytes which
was a finding not observed with serum from other clinical individuals [147]. Surprisingly, there
was a significant correlation between the adherence of normal lymphocytes and the production
of interleukin (IL)-1β with spontaneous secretion of IL-10 [147]. The effects noted were not a
result of diminished viability or alteration in the expression of the cell surface markers HLA-
DR and CD14 [147]. This study indicates that monocyte function is dampened in MF patients
[147]. A previous study in Sri Lanka and India demonstrated that 30% of Sri Lankan patients
with elephantiasis and 28% of Southern Indian patients with elephantiasis were significantly
associated with HLA-B*15 compared to 4% of Sri Lankan controls and 10% of Southern Indian
controls [148]. Filarial specific IgG and IgE concentration elevation have been observed in TPE
[149]. Peripheral basophils from patients with TPE was released more greater amounts of
histamine when they were challenged with Wuchereria or Brugia antigens than with Dirofilar‐
ia antigen [149]. This indicated that TPE resulted from immunological hyperresponsiveness to
human filarial parasites [149]. Leukocyte adhesion phenomenon in sera from patients with
TPE using Wuchereria bancrofti revealed maximal positive results compared with Dirofilaria
immitis and Dirofilaria repens [150]. Demonstration of living adult Wuchereria bancrofti in the
lymphatic vessels of the spermatic cord of the patients with TPE is evidenced by ultrasound
examination [151] and biopsy of a lump in the spermatic cord shows degenerating adult female
filarial worm with uteri full of microfilariae [152]. There is a marked reduction of filarial-
specific IgG and IgE levels in the lung epithelial lining fluid [153] and roentgenological
improvement [154, 155] after 6-14 days of therapy with dethylcarbamazine citrate (DEC). The
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standard treatment recommended by the World Health Organization is oral DEC (6 mg/kg/
day) for three weeks [156]. The usefulness of DEC in the treatment of TPE further focuses
attention on its filarial etiology [157, 158].
6. Pulmonary malaria and HLA
Four types of malarial parasites (Plasmodium falciparum, Plasmodium malariae, Plasmodium vi‐
vax, and Plasmodium ovale), the protozoa of the genus Plasmodium causes malaria and is pri‐
marily transmitted by the bite of an infected female Anopheles mosquito to infect humans
[159]. A previous study in a Thai population demonstrated that the allele frequencies of
HLA-B*46, -B*56, and -DRB1*1001 were statistically different between non- cerebral severe
malaria and cerebral malaria, between mild malaria and non-cerebral malaria, and mild ma‐
laria and cerebral malaria, respectively [160]. A recent study revealed that the NK cell reper‐
toire shaped by the KIR2DL3-HLA-C1 interaction demonstrates certain functional responses
that facilitates the development of cerebral malaria [161]. The frequency of the KIR2DL3-
HLA-C1 combination was found to be significantly lower in malaria high-endemic popula‐
tions [161]. This indicates that natural selection has reduced the frequency of the KIR2DL3-
HLA-C1 combination in in malaria high-endemic populations because of the propensity of
interaction between KIR2DL3 and C1 to favor development of cerebral malaria [161]. Young
et al conducted a study in Mali and Gambia and reported that either malaria parasite types
cp26 or cp29 were found to be less, not more common in Mali population with HLA-B*35
(37%) compared to non-HLA-B*35-bearing hosts (55%) whereas 51% of HLA-B*35-bearing
Gambian population were infected with either cp26 or cp29 compared to 42% of non-HLA-
B*35-bearing hosts [162]. A previous study in West African children demonstrates that HLA-
Bw*53, -DRB1*1302, and -DQB1*0501 which are common in West Africans are
independently associated with protection from severe malaria [163]. HLA-DR*04 alleles
were observed more frequently among patients with severe malaria [164]. Additionally, car‐
riers of the amino acid methionine at position 11 of the DPA1 allele were more often infected
with merozoite surface antigen (MSA)-1 K1 malaria parasites and less frequently with
MSA-1 RO33 malaria parasite infection [164]. The main finding of patients with falciparum
malaria which is the most deadly type of malaria infection is sequestration of erythrocytes
containing mature forms of Plasmodium falciparum in the microvasculature of the organs and
is quantified by measurement of Plasmodium falciparum specific histidine-rich protein 2
(PfHRP2) using a quantitative antigen-capture enzyme-linked immunosorbent assay [159].
Gas exchange is significantly impaired in patients with severe malaria [165]. The gold stand‐
ards for the diagnosis of malaria are light microscopic examination of thin and thick stained
blood smears [78, 166]. Human urine and saliva PCR detection of Plasmodium falciparum has
been introduced [166]. In severe falciparum malaria, the roentgenographic presentations in‐
clude diffuse interstitial edema, pulmonary edema, pleural effusion, and lobar consolidation
[166]. Intravenous chloroquine is the drug of choice for chloroqiune-susceptible Plasmodium
falciparum infections and those rare cases of life-threatening malaria caused by Plasmodium
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vivax, Plasmodium malariae, and Plasmodium ovale [78, 166]. A point mutation in the Plasmodi‐
um falciparum chloroqiune-resistance transporter (PfCRT) gene is responsible for chloro‐
qiune-resistant falciparum malaria [167] whereas diaappearance of the K76T mutation in
PfCRT is associated with chloroquine susceptibility [168]. Oral artemisinin -based combina‐
tion therapies (artesunate + mefloquine, artesunate + sulfadoxine-pyrimethamine, artesunate
+ amodioquine, or artemether + lumefantrine) are the best antimalarial drugs [169, 170]. Ad‐
ditionally, the World Health Organization (WHO) recommends oral treatment of dihydroar‐
temisinin plus piperaquine as soon as the patients is able to take oral medication but not
before a minimum of 24 hours of parenteral treatment [171]. The WHO recommended that
intravenous artesunate can be used preferentially over quinine for the treatment of severe
malaria caused by any Plasmodium species in both children and adults [172]. Oral artemisi‐
nin-based combination therapies have also demonstrated equivalent (if not better) efficacy
in the treatment of uncomplicated malaria caused by all Plasmodium species and chloro‐
quine-resistant Plasmodium vivax in both children and adults [172]. Hence, conventional
therapeutic regimens continue to be efficacious [172]. Insecticide-treated bed-nets in which
insecticide is incorporated into the net fibers is evidenced to be the best way to prevent ma‐
laria [173]. It is demonstrated that RTS, S/ASO2, a vaccine has demonstrated promising re‐
sults in endemic areas [173].
7. Pulmonary amoebiasis and HLA
Pulmonary amoebiasis that caused by the protozoan parasite, Entamoeba histolytica occurs
mainly by the extension from the amoebic liver abscess [174, 175]. In a nine-year prospective
study in a cohort of preschool children in Dhaka, Bangladesh demonstrated that a single amino
acid polymorphism (Q223R) in the leptin receptor was associated with increased susceptibility
to Entamoeba histolytica infection [176]. Children with two arginine alleles (223R) were nearly
four times more likely to infect with Entamoeba histolytica as compared to those homozygous
for glutamine (223Q) [176]. An in vitro study demonstrated that leptin signaling protected
human epithelial cells from amoebic killing via a STAT3- dependent pathway [177]. It was
identified that children who were heterozygous for the HLA class II DQB1*0601/DRB1*1501
haplotype were more likely to Entamoeba histolytica negative [178]. The immune mechanism
that explains why only a subset of Entamoeba histolytica-exposed persons develops clinical
disease is not fully understood [179]. The effect of microbiota on immune response to Entamoeba
histolytica and its virulence is not yet known [179]. The presence of cysts or trophozoites of
amoeba in the stool does not imply that the disease is caused by Entamoeba histolytica as other
two non-pathogenic species found in humans (Entamoeba dispar and Entamoeba moshkovskii) are
morphologically indistinguishable, but can be rapidly, accurately, and effectively diagnosed
by a single-round PCR [78, 180, 181]. Other diagnostic methods include culture of Entamoeba
histolytica, ELISA, indirect fluorescent antibody test (IFAT), and indirect hemagglutination test
(IHA) [78, 180, 181]. A combination of serological tests with identification of the parasite by
PCR or antigen detection is the best diagnostic approach [182]. Active trophozoites of
Entamoeba histolytica can be identified in sputum or pleural specimen [78]. Physical examina‐
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tion reveals fever, chest pain, tender hepatomegaly, and cough are indicated pleuropulmonary
amoebiasis [78]. Some patients may present with hemoptysis, expectoration of anchovy
source-liked pus, respiratory distress, and shock [78]. Chest roentgenographic findings include
pleural effusion, basal pulmonary involvement, and elevation of hemidiaphragm [78].
Metronidazole is the treatment of choice [183]. Diloxanide furoate, a luminal amoebiacidal
drug can eliminate intestinal Entamoeba cysts [184]. Lactoferrin and lactoferricins, amoebicidal
drugs, can be co-administered with a low dose of metronidazole to reduce metronidazole
toxicity [184]. Identification of possible vaccine candidates against amoebiasis are in progres‐
sive studies [185].
8. Pulmonary leishmaniasis and HLA
Pulmonary or visceral leishmaniasis, also called “ Kala azar ” is caused by Leishmania donova‐
ni and and Leishmania chagasi or infantum [186] is transmitted by various species of Pheboto‐
mus, a type of sand fly [187]. Leishmania amastigotes can be identified in pulmonary septa,
alveoli, and the BAL fluid [188, 189]. Pleural effusion, mediastinal lymphadenopathy, and
pneumonitis have been reported in HIV-infected patients with visceral leishmaniasis and lung
transplant patients [188, 189]. The expansion of the HIV- infection/AIDS epidemic over
leishmaniasis, particularly visceral leishmaniasis endemic regions has increased the number
of co-infected patients [190] indicating that visceral leishmaniasis is an opportunistic disease
in HIV-infected/AIDS patients although not yet considered an AIDS-defining disease [191].
According to sharing of immune-compromising mechanisms of both infections with Leishma‐
nia infantum and HIV-1 that may affect the parasite control in visceral leishmaniasis co-infected
patients [191]. In comparison to patients with visceral leishmaniasis alone, co-infected patients
present a more severe disease with increased parasite burden, frequent relapses, and anti‐
leishmanial drug resistance [190, 192]. On the other hand, Leishmania infection can impair
both the chronic immune activation and the lymphocyte depletion and can accelerate pro‐
gression to AIDS, particularly in HIV-1-infected individuals [193, 194]. Hence, serological
testings for latent infection due to Leishmania species are indicated in the pre-transplantation
screening from endemic areas [195]. A recent study in two populations from Brazil (cases) and
India (controls) demonstrated that the HLA-DRB1-HLA-DQA1 HLA class II region strongly
contributed to visceral leishmaniasis susceptibility, indicating shared risk factors for visceral
leishmaniasis that cross the epidemiological divides of geography and parasite species [196].
Several previous studies of Leishmania donovani in mice model demonstrated dramatic
differences in visceral disease in spleens and livers in congenic mice with different H-2
haplotypes [197]. There was evidenced that noncuring and curing responses mapped to the
HLA-class II molecules by using recombinant congenic mice [198] and functional analysis
blocking IA or IE (corresponding to DQ and DR, respectively) molecules in vivo with mono‐
clonal antibodies [199]. A significant role for CD8+ T-cells has also been shown in Leishmania
donovani [200, 201]. A previous case-control study in Tunisia demonstrated that visceral
leishmaniasis was associated with DR/DQ class II genes but not with TNF/LTA or HSP70 class
III loci [202]. Associations between delayed-type hypersensitivity-positive asymptomatic
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persons and TNF alleles were identified [203]. Positive associations between polymorphisms
and various clinical phenotypes for cutaneous leishmaniasis have been demonstrated in a
number of small case-control studies [204]. A recent study demonstrated a trend towards
susceptibility to cutaneous leishmaniasis for alleles HLA-DRB1*13, HLA- B*35, and HLA-
B*44 [205]. HLA-B*49 allele tended towards susceptibility to recurrent American cutaneous
leishmaniasis (ACL), and HLA-B*52 to re-infection whereas presence of HLA-B*45 tended
towards protection of against the cutaneous form of ACL [205]. A*02B*44 DRB1*07 and
A*24B*35 DRB1*01 alleles, the most frequent haplotypes may be associated with susceptibility
to ACL [205]. Immune activation can profoundly impact the visceral lieshmaniasis clinical
course and prognosis, leading to increase the risk of death even under treatment of leishma‐
niasis [206]. Pentavalent antimonials, pentamidine, and amphotericin B, particularly the
liposome formulations, and miltefosine are the drugs for the treatment of lieshmaniasis [207].
A previous study demonstrated that Poly/hsp/pcDNA vaccine can significantly decrease
parasite load in spleen and liver indicating a feasible, effective, and practical approach for
visceral leishmaniasis [208].
9. Pulmonary trypanosomiasis and HLA
Human African trypanosomiasis (HAT) or sleeping sickness is caused by an extracellularly
protozoan parasite, called “ Trypanosoma brucei gambiense ” [209], “Trypanosoma brucei rhode‐
siense ” [210] and “ Trypanosoma cruzi ” which was discovered by Carlos Chagas in 1909 [211]
and endemic to West Africa and Central Africa, mostly in Democratic Republic of Congo,
Angola, Chad, Central African Republic, Uganda, and Sudan [209]. HAT continues to threat
more than 60 million people in 36 sub-Saharan countries [209, 212]. In mice model, hypercel‐
lularity and edema of alveolar walls, approximately 10 times thicker than normal alveolar wall
are identified and results in wall thickening although parasites are not demonstrated in alveoli
[211]. Thickening and edema of bronchial walls of small and medium size bronchi due to
parasite infiltration and significant inflammatory reaction (except large bronchi) in mice model
were observed [211]. These bronchial inflammatory changes result in bronchial lumen
reduction [211]. Most infected mice demonstrated infiltration of the walls of large blood vessels
with extensive clusters of parasites in the myocytes of the muscular stratum and accompanying
by an inflammatory reaction, interstitial edema, and rupture of muscle fibers [211]. These
pathologically lung changes can contribute to pulmonary alveolar hemorrhage, bronchiolitis,
and pneumonitis [211]. Pulmonary emphysema was also observed in the lungs of infected rats
[213]. By the statistical analysis, the difference between experimental groups in lung-parasitic
distribution and the degree of inflammatory reaction demonstrated no statistical difference
[211]. Most Mexican strains demonstrated cardiomyotropism [211] and could cause pulmo‐
nary hypertension that could result in a dilatation of the right ventricle which is a typical
characteristic of Chagas’ disease caused by Trypanosoma cruzi without affecting the left
ventricle [211]. However, many cases of Chagas’ disease with pulmonary hypertension
associated with right ventricular dilatation could attribute to left ventricular failure [214].
Several HLA alleles and haplotype associated with Chagas’ disease have studied [215]. The
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highly polymorphic HLA class I (A, B, and C) and II (DR, DQ, and DP) molecules determine
the efficiency of presentation of Trypanosoma cruzi epitopes to CD8+ and CD4+ T-cells, respec‐
tively [215]. A previous study in Mexican population demonstrated that HLA –B*39 and HLA-
DR4 alleles were associated with Trypanosoma cruzi infection while HLA-A*68 and HLA-
DR16 allele were markers of protection of development of chronic Chagas’ cardiomyopathy
(CCC) and heart damage susceptibility, respectively [216]. Another study in Mexico revealed
that HLA-B*39 and HLA-DR*4 alleles were also more frequently identified in patients with
Chagas’ disease [1]. A previous study in south-eastern Brazil demonstrated that HLA-A*30
and HLA-DQB1*06 alleles were associated with susceptibility to Chagas’ disease and protec‐
tion of Chagas’ disease, respectively in regardless of the clinical form of the disease, respec‐
tively [217] while HLA-DR2 allele was associated with susceptibility to chronic Chagas’ disease
[218]. Nevertheless, in another previous study revealed that polymorphism of HLA-DR and
HLA-DQ alleles did not influence on the susceptibility to different clinical forms of Chagas’
disease or the progression to severe Chagas’ cardiomyopathy [219]. A study in Chile, it was
found that HLA-B*40 antigen in the presence of Cw3 was significantly lower in patients with
CCC [220] and was higher expressed in subjects without cardiac disease in the city of Santiago
[221]. A previous study in Venezuela in comparison of HLA class II allele frequencies between
patients with Chagas’ disease and controls demonstrated a higher frequency of DQB1*0501,
DRB1*01, and DRB1*08 alleles, and a decreased frequency of DQB1*0303 and DRB1*14 alleles
whereas patients with congestive heart failure and arrhythmia revealed decreased frequency
of DRB1*1501 allele [222]. A higher frequency of the HLA-DPB1*0401 allele and DPB1*0401-
HLA-DPB1*2301 or DPB1*0401-DPB1*3901 haplotype was identified in patients with cardiac
manifestations in an endemic area of central Venezuela [223] whereas susceptibility between
HLA-C*03 allele and CCC was confirmed [224]. In several Latin American mestizos from
different countries and patients with CCC, there was an increase frequency of HLA-A*31, -
B*39, and -DR8 alleles and a decrease of frequency of HLA-DQ1, -DQ3, -DR4, and -DR5 alleles
[225]. A study in Bolivia revealed that HLA-DRB1*0102, - DRB*1402, and MICA*011 alleles
were in strong linkage disequilibrium and there was association between the HLA-DRB1*01-
B*14-MICA*011 haplotype and the resistance against chronic Chagas’ disease whereas the
frequencies of HLA-DRB1*01 and HLA- B*1402 alleles were significant lower in patients with
electrocardiogram alteration and/or megacolon compared with a group of patients with
indeterminate clinical form [226]. In a study in Argentine population, the class II alleles HLA-
DRB1*0409 and HLA-DRB1*1503 were significantly more prevalent in Chagas’ disease and
HLA-DRB1*1103 allele was associated with Chagas’ disease resistance whereas increased
frequency of DRB1*1503 allele was identified in patients with CCC [227, 228]. A previous study
on treatment of relapsing trypanosomiasis in Gambian population demonstrated that a 7-day
course of intravenous eflornithine was satisfactory and would result in substantial savings
compared with the standard 14-day regimen although the prior regimen was inferior to the
standard regimen and could be used by the national control programmes in endemic areas,
provided that its efficacy was closely monitored whereas melarsoprol remains the only
effectively therapeutic option for new cases [229]. In animal experimental studies, eflornithine
and melasoprol synergistically act against trypanosomes since the former drug decreases the
trypanothione production, the target of the latter drug [230, 231]. A recent study demonstrated
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that oxidative stress could contribute to parasite persistence in host tissue and the development
of anti-Trypanosoma cruzi drugs [232].
10. Pulmonary larval migrans
Toxocara larval migrans caused by Toxocara canis, a parasite in dogs’ intestine and Toxocara
catis, a parasite in cats’ intestine infected intermediate host, humans by ingestion these em‐
bryonated Toxocara eggs which hatch into infective larvae in the human intestine [78]. The
infective larvae then penetrate the intestinal wall and are carried by blood circulation to
many organs including lungs, liver, central nervous system, eyes, and muscles [78]. Granu‐
lomata then occur in these organs and later develop fibrosis and calcification [78]. A previ‐
ous study indicated that Toxocara species infections were associated with a polarized CD4
Th2-dominat immunity and eosinophilia, mediated mainly be HLA class II molecules, and
Foxp3+ CD4+CD25+-expressing T regulatory (Treg) cells play a role in regulation of the im‐
munopathology of Toxocara granulomas in experimental animals and in enhancing the ex‐
pression of TGF-β1, which is an important function of Treg demonstrated during Toxocara
canis invasion in the mouse’ s brain [233]. The potential susceptibility loci HLA class II mole‐
cules are considered to be involved in regulation of a Th2-dominant immunity which is
highly controlled by stimulation through TGF-β1 [233]. Exploration of TGF-β1 polymor‐
phism, Fox3+ CD4+CD25+ Treg cells permit insight into the contribution produced by envi‐
ronmental and genetic factors in influencing disease syndrome type and severity in human
toxocariasis [233]. Pulmonary manifestations are found in 80% and present with severe asth‐
ma [78]. Clinical manifestations may demonstrate scattered rales and rhonchi on ausculta‐
tion including fever, cough, hepatosplenomegaly, generalized lymph node enlargement, eye
pain, strabismus, white pupil, unilaterally visual loss, abdominal pain, and neurological
manifestations [78]. Some cases may present with severe eosinophilic pneumonia and may
contribute to respiratory distress syndrome [234-236]. Chest roentgenogram may demon‐
strate localized patchy infiltrates [78]. This syndrome is usually associated with eosinophilia,
elevated antibody titers to Toxocara canis, and increased total serum IgE level [237, 238].
About 25% of childhood patients have no eosinophilia [239]. Identification of serum IgE an‐
tibodies by ELISA [240] and Toxocara excretory-secretory antigens by Western-blotting
method have been reported for diagnosis [241]. Nevertheless, serodiagnostic methods can‐
not distinguish between past and current infections [240, 241]. Toxocara eggs or larvae can‐
not be identified in the feces since human is not the definitive host [78]. Histopathological
examination of lung or liver biopsy specimens may reveal granulomas with multinucleated
giant cells, eosinophils, and fibrosis [78]. Toxocara larval migrans may be spontaneous reso‐
lution, therefore, mild to moderate symptomatic patients need not any treatment [78]. How‐
ever, patients with severe Toxocara larval migrans can be treated with diethylcarbamazine 6
mg/kg/day, 21 days) [242], mebendazole (20-25 mg/kg/day, 21 days) [243] or albendazole (10
mg/kg/day, 5 days) [244]. Exacerbation of the inflammatory reactions in the tissues due to
killing of the larvae may occur, therefore, antihelminthics plus corticosteroids is recom‐
mended [78].
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11. Pulmonary toxoplasmosis and HLA
A celled protozoan parasite, called “ Toxoplasma gondii ” which are primarily carried by cats
is causal microorganism [245]. Humans are infected by ingestion of parasitic cyst- contami‐
nated uncooked milk product, vegetables or meat [78]. The clinical manifestations are influ‐
enza-liked illness, myalgia or enlarged lymph nodes [78] which is the most common
recognized clinical manifestation [246]. Pulmonary involvement has been increasingly re‐
ported in HIV-infected/AIDS patients [78]. Pulmonary manifestations may be interstitial
pneumonia, diffuse alveolar damage or necrotizing pneumonia [247]. Nevertheless, obstruc‐
tive or lobar pneumonia has been reported in a 49-year-old Spanish heterosexual man [246].
Early pregnancy with toxoplasmosis can cause fetal death, and chorioretinitis and neurolog‐
ical symptoms in the newborn whereas chronic disease can cause chorioretinitis, jaundice,
convulsion, and encephalitis [78]. Association between the HLA-DQ*3 allele and the suscept‐
ibility to toxoplasmic encephalitis in HIV-infected/AIDS patients has been reported [248]. A
previous study among Caucasians demonstrated that the DQ3 gene frequency was signifi‐
cantly higher in infected infants with hydrocephalus than subjects without hydrocephalus
[249]. In infected- mice model, human major histocompatibility MHC-class II transgenes re‐
duced parasite burden and brain necrosis that was consistent with the observed association
between HLA-DQ*3 allele and hydrocephalus in human infants [249]. In the murine model,
the DQ3 (DQ8, DQB1*0302) gene protected less than DQ1 (DQ6, DQB1*0601) [249]. These
significant findings can provide characterization of the human immune responses that are
pathogenic or protective in Toxoplasma gondii infections. Diagnosis of toxoplasmosis is based
on detection of the protozoan parasites in the body tissues [78]. Sputum examination was
used in diagnosis of pulmonary or disseminated toxoplasmosis in a 14-year-old allogeneic
bone marrow recipient with graft- versus-host disease by identification of Toxoplasma gondii
tachyzoites in sputum smears [250]. Serodiagnosis is unable to discriminate between active
and chronic Toxoplasma gondii infection due to ability to increase the antibody levels without
active disease [78]. A real-time-PCR-based assay in BAL fluid has been performed in HIV-
infected/AIDS patients [251]. Toxoplasmosis can be treated with a combination regimen of
pyrimethamine and sulfadiazine [78].
12. Pulmonary dengue viral infection and HLA
This disease is caused by dengue virus (DENV) that belong to the family Flaviviridae, genus
Flavivirus, and is transmitted to humans by Aedes mosquitoes, mainly Aedes aegypti [252].
Four serotypes of virus have been identified ; DENV-1, DENV-2, DENV-3, and DENV-4
[252]. An estimated 50 million-infected people occur each year and more than 2.5 billion
people are being at risk of infection [253]. Epidemic with high incidences of dengue hemor‐
rhagic fever have been linked to primary infection with DENV-1 followed by infection with
DENV-2 or DENV-3 whereas it indicated that the longer the interval between primary and
secondary infections, the higher the risk of developing severe disease [254-256]. In adults,
primary infections with each of four DENV serotypes, especially with DENV-1 and
DENV-3, frequently results in dengue fever whereas some outbreak of primary infections
with DENV-2 have been predominantly subclinical [257]. However, adult- dengue infec‐
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tions are frequently accompanied by a tendency for severe hemorrhage [258] and can be life-
threatening when infections occur in patients with chronic diseases such as asthma and
diabetes [259-261]. Several HLA class I alleles, female sex, AB blood group, a single-nucleo‐
tide polymorphism in the tumor necrosis factor gene, and a promoter variant of the DC-
SIGN receptor gene are the host factors that increase the risk of severe dengue disease
[262-267]. Notably, the first outbreak in the Americas occurred in 1981, which coincided
with the introduction of the possibly more virulent DENV-2 Southeast Asian genotype
whereas the less virulent indigenous DENV-2 genotype was already circulating in the re‐
gion [259, 268-270]. Age has been demonstrated to influence the disease outcome following
a secondary infection with heterologous DENV [271]. In Asia, the risk of severe disease is
greater in children than in adults, in contrast to the Americas [272, 273]. Nevertheless, the
finding that dengue hemorrhagic fever or dengue shock syndrome is noted primarily in a
relative small percentage of secondary DENV infections and to a much lesser extent in pri‐
mary infections although with virulent strains indicates that host factors must be critical de‐
terminants of severe DENV disease development [252]. There is evidence that DENV
antigen is present in the pulmonary vascular endothelium [274] whereas liver is the organ
commonly involved in human DENV infections including mouse model [275, 276]. Glu‐
cose-6-phosphate dehydrogenase deficiency which is highly prevalence identified among
African population [277] can cause abnormal cellular redox, therefore affecting production
of hydrogen peroxide, superoxide, and nitric oxide indicating oxidative stress [278]. Viral
proliferation and virulence by increasing viral receptors on target cells or increasing of viral
particles is known to be affected by oxidative stress [278], therefore, glucose-6-phosphate de‐
hydrogenase deficiency may contribute to increased replication of DENV in monocytes
[277]. Several human HLA class I alleles (-A*01, -A*0207, -A*24, - B*07, -B*46, -B*51) [262,
264, 279] and HLA class II alleles (-DQ*1, -DR*1, -DR*4) [263, 280] are associated with devel‐
opment of dengue hemorrhagic fever. Additionally, a recent study demonstrated that signif‐
icantly higher frequency of HLA-A*33 allele in dengue fever patients, HLA-A*0211 allele in
dengue hemorrhagic fever cases compared to controls and dengue fever cases, respectively
[281]. The frequency of HLA-B*18 and HLA-Cw*07 alleles were significantly higher in
DENV-infected cases compared to controls [281]. The combined frequency of HLA-Cw*07
with HLA-DRB1*07/*15 genotype was significantly higher in dengue hemorrhagic fever cas‐
es as compared to dengue fever cases and controls but the frequency of combination of
HLA-Cw*07 allele without HLA-DRB1*07 allele was significantly higher in dengue fever cas‐
es compared to controls [281]. This study results indicate that HLA-A*33 allele may be asso‐
ciated with development of dengue fever whereas HLA-B*18 and HLA-Cw*07 alleles may be
associated with symptomatic dengue infection requiring hospitalization [281]. A previous
study demonstrated that HLA-A*0207 and HLA-B*51 alleles was associated with dengue
hemorrhagic fever in patients having secondary DENV-1 or DENV-2 infection only and chil‐
dren with HLA-A*24 allele were more likely to develop dengue hemorrhagic fever [282]. Af‐
ter secondary dengue infections, HLA-B*44, -B*62, -B*76, and -B*77 alleles revealed to
protect against development of clinical disease [282]. Clinical findings in early febrile stage
include fever, headache, malaise, rash, body pain, and later develops pleural effusion [258,
283], both lower lobes infiltration [283], bilateral perihilar edema [284], ascites, bleeding,
thrombocytopenia (platelet < 100,000 per mm3), hematocrit > 20%, and clinical warning signs
such as restlessness, severe and continuous abdominal pain, persistent vomiting and a sud‐
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den reduction in body temperature associated with profuse perspiration, adynamia (vigor
or loss of strength) and sometimes fainting which can be indicative of shock due to plasma
extravasation [258]. Dengue disease must be excluded from two syndromes related to hanta‐
virus, hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary
syndrome (HPS) in Americas [285-287]. HPS is typically characterized by acute noncardio‐
genic pulmonary edema and circulatory shock whereas fever, hemorrhagia, and acute renal
failure are hallmark findings in HFRS [288]. Laboratory diagnosis of DENV infection in‐
clude virus isolation, serodiagnostic tests (MAC-ELISA, IgG ELISA, IgG : IgM ratio, neutral‐
ization assay), nucleic acid-amplification tests (real-time PCR, reverse-transcriptase PCR,
nucleic acid- sequence based amplification assay (NASBA)), and antigen detection (NS1 an‐
tigen and antibody detection) [258]. DENV complications include massive hemorrhage, dis‐
seminated intravascular coagulation, non-cardiogenic pulmonary edema, respiratory
failure, and finally develops multiple organ failure [258]. In uncomplicated dengue cases,
treatment is only supportive, but in cases with prolonged or recurrent dengue shock, intra‐
venous fluids should be administered carefully according to dosage and age to prevent pul‐
monary edema [258]. DENV control and prevention strategies include vector control and
vaccine development [258]. Current approaches to vaccine development involve using deox‐
yribonucleic acid vaccine, chimeric viruses using yellow fever vaccine, subunit vaccine, in‐
activated viruses, attenuated viruses, and attenuated dengue viruses as backbones [289-294].
An Acambis/Sanofi Pasteur yellow fever-dengue chimeric vaccine is in advanced Phase II
testing in children in Thailand [258]. A possible licensed vaccine will be available in less
than 10 years [258].
13. Pulmonary leptospirosis and HLA
Leptospirosis is a zoonotic disease caused by genus Leptospira which belongs to the phylum
of spirochaetes [295]. The 8 pathogenic species of this genus are Leptospira interrogans, Lepto‐
spira borgpetersenii, Leptospira noguchii, Leptospira santarosai, Leptospira kirschneri, Leptospira al‐
stonii, Leptospira alexanderi, and Leptospira weilii [295]. Transmission of leptospirosis requires
continuous enzoonotic circulation of the pathogen among animal reservoir or as commonly
referred-maintenance host [295]. Leptospira serovars reveal specific host preferences with re‐
gard to their ability to produce high-grade carriage [295]. Rats (genus Rattus) serve as reser‐
voirs for the Icterohaemorrhagiae serogroup while house mice (Mus musculus) are the
reservoir for the Ballum serogroup [295]. Additionally, serovars often do not cause signifi‐
cant disease in highly adapted-reservoir hosts [295]. A previous study demonstrated that
HLA-DQ*6 allele increased risk of laboratory-confirmed leptospirosis [296]. Pathogenic spe‐
cies produce a systemic infection after an environmental exposure, establish persistent renal
and urinary shedding in reservoir animals and cause tissue damage in multiple organs of
susceptible hosts [295]. Humans are incidental hosts in which leptospirosis produces acute
disease manifestations and does not induce a disease carrier state [295]. The incubation peri‐
od varies from 2 to 30 days [295]. Clinical presentation in human leptospirosis includes
acute febrile illness that often cannot be differentiate from other causes of acute fever illness
[295]. The clinical manifestations include fever, headache, myalgia (especially calf muscle),
and prostration associated with any of the following symptoms or signs: cough, hemoptysis,
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breathlessness, conjunctival suffusion, jaundice, oliguria or anuria, internal organ hemor‐
rhages, skin rash, cardiac arrhythmia or failure, and meningeal irritation [297]. Leptospiro‐
sis-associated pulmonary hemorrhage syndrome was first described in China and Korea
and then was brought to global attention by a large outbreak of severe-from disease in Ni‐
caragua in 1995 [295]. The risks of developing severe leptospirosis include a critical thresh‐
old of qPCR- determined leptospiremia, identification of the infective strain, and early
laboratory results [298]. The illness usually resolves after the first week of symptoms [295].
The presumptive diagnosis was made from a positive result of a rapid screening test such as
latex agglutination test, IgM ELISA, dipstick, lateral flow, etc [297]. The confirmatory diag‐
nosis includes isolation of the organism from blood or other clinical specimens, a positive
PCR result, and fourfold or greater rise in titer or seroconversion in microscopic agglutina‐
tion test (MAT) on paired samples obtained at least 2 weeks apart [297]. Severe case usually
treated with intravenous benzylpenicillin (30 mg/kg up to 1.2 g intravenously and 6-hourly
for 5-7 days) [297]. Oral administration of doxycycline (2 mg/kg up to 100 mg, 12-hourly for
5-7 days), amoxicillin, ampicillin, or tetracycline is the treatment of choice in less severe cas‐
es [297]. The third-generation cephalosporins, such as ceftriazone and cefotaxime, quinolone
antimicrobials may also be effective, but Jarrisch-Herxheimer reactions can occur after the
start of antimicrobial treatment [297]. The patients should be appropriate monitored and
care supported, such as mechanical ventilation, dialysis, etc [297]. A recent study in Thai‐
land demonstrated that only the latex test could be considered cost-effective when com‐
pared to the no-antimicrobial option, and that latex test, microcapsule agglutination test,
and lateral flow were still inferior to empirical treatment (7-day course of doxycycline, 100
mg bid treatment) [299]. A recent study on vaccine candidates for protection of leptospirosis
successfully demonstrated LBJ_2271 as a protein candidate for further study of antigenic im‐
mune stimulation for vaccine development [300] whereas another recent study revealed that
czcA and its four subunit vaccine peptides could be ideal T-cell driven efficacious vaccine
against this disease [301]. Until epidemiologically-validated immune correlates are deter‐
mined and discovery of vaccine candidates will likely continue to rely on the search for new
virulence factors and outer membrane proteins of the organism.
14. Conclusions
Most of several studies have inconclusively demonstrated statistical association between HLA
class I and II molecules and susceptibility to a range of complex tropical pulmonary infectious
diseases, particularly parasitic pulmonary diseases. The globalization of neglected tropical
pulmonary infectious diseases can alert the healthcare providers in diagnosis in recent
immigrants or travelers from endemic areas who present with respiratory manifestations and
peripheral blood or tissue eosinophilia. A complete re-evaluation of the true impact of
HLA/MHC genes on susceptibility to tropical pulmonary infectious diseases. Summary of
association between known HLA alleles and susceptibility of some tropical pulmonary
infectious diseases are shown in Table 1.
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Disease Known HLA Influence Reference
SARS HLA-B*0703, HLADRB1*0301 More prevalent and
more poorer outcome 7, 8
CXCL10(-938AA)/Fg12(+158T/*) or CXCL10(-938AA)/
HO-1(-497A/*)
Protective 10
Fg12(+158T/*) Susceptible 10
Tuberculosis HLA-DQB1*0601, HLA-DRB1*1501HLA-DPB1*02, HLA-
DRB1*0803, HLA-DQA1*0101, HLA-DQB1*0501HLA-
DRB1*1501, HLA-DQB1*0502, HLA-DQB1*0503
Susceptible
26, 27, 28, 29
HLA-DQB1*0402 Decreased frequency 28
HLA-B*17-tumor-necrosis-factor-α-238/A, HLA-tumor-
necrosis-factor-α-308/2, HLA-tumor-necrosis-factor-β-2
Relapse 30
HIV-Infection/AIDS HLA-B*27, HLA-B*57 Slow progression 33
HLA-A*24 More rapid central
nervous system
impairment
33
HLA-Cw*2 Protective against
disease progression 33
HLA-DQB1*2 Protective against
both disease
progression and
central nervous
system impairment
33
HLA-A*31, HLA-B*41, HLA-DQB1*5, HLA-DRB1*10 Susceptible to TB
disease 39
Filariasis CD8+ HLA-DR+ Susceptible to
chronically
obstructive lymphatic
form
146
HLA-B*15 Susceptible 148
Malaria HLA-B*46, HLA-B*56, HLA-DRB1*1001, HLA-B* Susceptible 160, 162
KIR2DL3-HLA-C1, HLA-Bw*53, HLA-DRB1*1302, HLA-
DQB1*0501
Protective 161, 163
Amoebiasis HLA-DQB1*0601/DRB1*1501 Protective 178
Leishmaniasis HLA-DRB1, HLA-DQA1 Susceptible to visceral
or pulmonary
leishmaniasis
196
HLA-DRB1*13, HLA-B*35, HLA-B*44, HLA-A*02, HLA-
B*44, HLA-DRB1*07, HLA-A*24, HLA-DRB1*01
Susceptible to
cutaneous
leishmaniasis
205
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Disease Known HLA Influence Reference
HLA-B*49 Susceptible to
recurrent cutaneous
leishmaniasis
(American type)
205
HLA-B*52 Susceptible to re-
infected cutaneous
leishmaniasis
American type)
205
HLA-B*45 Protecive against
cutaneous
leishmaniasis
(American type)
205
Trypanosomiasis HLA-B*39, HLA-DR4, HLA-A*30, HLA-DQB1*0501, HLA-
DRB1*01, HLA-DRB1*08, HLA-DPB1*0401, HLA—
DPB1*2301, HLA-DPB1*3901, HLA-C*03, HLA-A*31,
HLA-B*39, HLA-DR8, HLA-DRB1*0409, HLA-DRB1*1503
Susceptible to
infection and
development of
Chagas’ disease
1, 216, 217,
222, 223,
224, 225,
227, 228
HLA-A*68, HLA-DR*16, HLA-DQB1*06, HLA-B*40, HLA-
DQB1*0303, HLA-DRB1*14, HLA-DRB1*1501, HLA-DQ1,
HLA-DQ3, HLA-DR4, HLA-DR5, HLA-DRB1*0102, HLA-
DRB*1402, HLA-MICA*011, HLA-DRB1*1103
Protective against
development of
chronic Chagas’
cardiomyopathy and
cardiac damage
216, 217,
220, 225,
226, 227,
228
Toxoplasmosis HLA-DQ*3 Human
hydrocephalus 249
HLA-DQ*6, HLA-DQB1*0601 Protective in murine
model 249
Dengue HLA-A*01, HLA-A*0207, HLA-A*24, HLA-B*07, HLA-
B*46, HLA-B*51, HLA-DQ*1, HLA-DR*1, HLA-DR*4, HLA-
A*0211, HLA-Cw*07 (in combination with HLA-
DRB1*07/*15 genotype)
Susceptible to
development of
dengue hemorrhagic
fever
263, 280,
281
HLA-A*33, HLA-HLA-Cw*07 Susceptible to
development of
dengue fever
281
HLA-B*18, HLA-Cw*07 Susceptible to
symptomatic dengue
infection
281
Leptospirosis HLA-DQ*6 Increased risk of
laboratory
confirmation
296
Table 1. Association between some Tropical Pulmonary Infectious Diseases and known Human Leukocyte Antigens
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